Core Viewpoint - The company reported a slight decline in revenue and net profit for the reporting period, but showed significant improvement in cash flow from operating activities, indicating a potential for recovery and growth in the future [6]. Financial Performance - The company achieved operating revenue of 3,369.38 million yuan, a year-on-year decrease of 0.43% [6]. - The net profit attributable to shareholders was 690.93 million yuan, down 0.91% year-on-year [6]. - The net profit after deducting non-recurring gains and losses was 662.20 million yuan, reflecting a year-on-year increase of 2.33% [6]. - The net cash flow from operating activities was 636.36 million yuan, showing a substantial year-on-year increase of 300.52% [6]. - Total assets at the end of the reporting period were 25,358.93 million yuan, an increase of 3.20% from the beginning of the period [6]. - The net assets attributable to shareholders were 15,796.89 million yuan, up 3.92% from the beginning of the period [6]. - The weighted average return on net assets was 4.43% [6]. Business Segments Medical Devices - The medical device segment generated the highest revenue, totaling 1,776.47 million yuan, with a year-on-year growth of 1.30% [7]. - The cardiovascular interventional business achieved revenue of 1,238.60 million yuan, a year-on-year increase of 7.57%, with coronary intervention contributing 881.23 million yuan (up 3.60%) and structural heart disease generating 328.71 million yuan (up 32.06%) [7]. - The surgical anesthesia business reported revenue of 241.01 million yuan, down 10.29% year-on-year [8]. - The in-vitro diagnostics business had revenue of 163.37 million yuan, a year-on-year decline of 17.35% [9]. Pharmaceuticals - The pharmaceutical segment reported revenue of 1,117.44 million yuan, a year-on-year decrease of 1.52% but a quarter-on-quarter increase of 79.34% [10]. - The retail channel inventory clearance is nearly complete, with a gradual increase in the revenue share of non-atorvastatin calcium and clopidogrel [10]. - The generic drug segment achieved revenue of 975.35 million yuan, up 3.89% year-on-year, while the raw materials segment saw revenue of 142.10 million yuan, down 27.44% year-on-year [10]. Medical Services and Health Management - The medical services and health management segment generated revenue of 475.47 million yuan, a year-on-year decrease of 4.05% [11]. - The company provides cardiovascular disease medical services and health management through specialized hospitals and e-commerce platforms [11]. - The Hefei Cardiovascular Hospital reported revenue of 83.44 million yuan, an increase of 3.51% year-on-year [11]. - The AI-based health management services, focusing on cardiac monitoring and rehabilitation, generated revenue of 284.38 million yuan, reflecting a year-on-year growth of 8.64% [11].